Exhibiting at FOOD INGREDIENTS CHINA 2025

Established in 1999, BIFIDO Co., Ltd. is a leading South Korean biotechnology company specializing in the development and production of high-quality probiotics and functional health supplements. With its headquarters and manufacturing facilities located in Hongcheon-eup, Gangwon Province, BIFIDO has become a globally recognized innovator in gut microbiome science and probiotic-based solutions.

Core Business

BIFIDO focuses on the research, fermentation, and commercialization of Bifidobacterium strains and related probiotic ingredients. The company offers a wide range of raw materials, finished products, and OEM/ODM solutions to the pharmaceutical, dietary supplement, and functional food industries. It has developed proprietary bacterial strains and fermentation technology to enhance gut health and immune function.

Product & Service Offerings

BIFIDO’s portfolio includes:

• Probiotic Strains:

  • Bifidobacterium bifidum BGN4
  • Bifidobacterium longum BORI
  • Bifidobacterium lactis AD011
  • These strains have been clinically studied and patented for their beneficial effects on intestinal health, immunity, and inflammatory response.

• Fermented Ginseng Products:

  • Fermented Ginseng Powder
  • Fermented Ginseng Extract
  • These products are derived through a patented fermentation process using probiotics, enhancing bioavailability and efficacy.

• Consumer Health Supplements (Zigunuk Brand):

  • Zigunuk Bifidus Premium
  • Zigunuk Bifidus Baby Premium
  • Functional supplements targeting adults, infants, and those with gastrointestinal issues.

• OEM/ODM Services:

  • Custom formulation and private label manufacturing of probiotic and functional health products.

Specialization and USP

BIFIDO is renowned for its core probiotic strains—BGN4 and BORI—isolated from healthy Korean infants and protected by multiple international patents. The company's major USP lies in:

• Targeted delivery systems ensuring high survival rates of probiotics through the digestive tract.
• Dual fermentation technology for enhanced efficacy and functionality.
• Clinical evidence-based product development supported by peer-reviewed publications.

Financial Overview

While the company is privately held and does not publicly disclose its financial statements, BIFIDO has been recognized by the Korean government as a Promising Export Enterprise and a KOSDAQ-listed supplier to major international markets. The consistent growth in international orders indicates solid financial performance and market trust.

Shipment Records

According to shipment intelligence from platforms like Volza and ImportYeti:

• BIFIDO has conducted hundreds of international shipments, mainly to the United States, Japan, China, and Europe.
• Frequent buyers include dietary supplement brands, infant nutrition companies, and pharmaceutical manufacturers.
• Notable clients include Kobayashi Pharmaceutical in Japan and direct collaboration with health supplement companies in the U.S.
• Exported products often include finished probiotics and raw probiotic cultures in bulk quantities.

Target Market

BIFIDO serves:

• Global nutraceutical companies
• Infant formula and pediatric nutrition brands
• Pharmaceutical companies
• Health and wellness product manufacturers
• Functional food producers

The company maintains a strong presence in Asia, North America, and the European Union, with increasing traction in the Middle East and Oceania.

Capabilities

• Proprietary probiotic strain bank and fermentation technology
• In-house R&D Center accredited by the Korean Ministry of Science and ICT
• Pilot and full-scale GMP-certified production facilities
• ISO 9001:2015 certified quality system
• Custom manufacturing capabilities for capsule, powder, and liquid forms

Certifications and Compliance

• GMP Certified
• ISO 9001
• HACCP
• Halal Certified
• Patent Portfolio covering strains like BGN4 and BORI
• Health Functional Food Certification by the Korean Ministry of Food and Drug Safety (MFDS)

Customer Testimonials

Although individual testimonials are not disclosed publicly, long-term export relationships and partnerships with global health companies attest to product satisfaction and clinical efficacy. Research studies and published trials conducted using BIFIDO’s strains have been cited by academic institutions and health journals.

Major Achievements

• Successfully commercialized patented probiotic strains BGN4 and BORI
• Exported to over 30 countries worldwide
• Recognized as a Promising SME Exporter by the South Korean government
• Partnered with research institutes like Seoul National University and Korea Food Research Institute
• Multiple scientific publications supporting the health benefits of proprietary strains
• Developed synbiotic solutions combining probiotics and prebiotics for enhanced gut health